Focused on Medicaid, the new pacts now involve more than just large pharmaceutical companies, but still aren’t expected to meaningfully impact drugmaker profits.
An article from
Trump administration
Focused on Medicaid, the new pacts now involve more than just large pharmaceutical companies, but still aren’t expected to meaningfully impact drugmaker profits.
Published Sept. 1, 2026
The North Lawn at the White House on June 21, 2025, in Washington, D.C.
The Trump administration is expected to announce voluntary drug-pricing agreements with midsize biotech companies, requiring…
Nine more drugmakers strike voluntary drug-pricing deals with the White House, pledging nearly $20B in US investments to avoid…
The deals will build on agreements the administration struck with 17 of the world’s largest drugmakers, including Pfizer, Eli…
The companies would agree to align prices on outpatient drugs for state Medicaid programs with what they charge in foreign…
Trump strikes MFN drug-pricing deals with 9 more drugmakers as Incyte joins quietly; Oz says 600K seniors signed up for CMS…
A deal with pharmaceutical companies may not be as far-reaching as the administration says, according to experts.
White House to announce new drug pricing deals with biotechs: Report
Trump announces nine new drug pricing deals, this time with midsize biotechs
Trump announces new drug pricing deals with 9 pharma companies
Three takeaways from the latest White House drug pricing event
What Trump's Most-Favored-Nation Deal Means for Drug Prices
Nine more drugmakers cut pricing deals with Trump
Trump announces deal with 9 new pharmaceutical firms in move to ease drug costs
Trump announces nine most-favored-nation deals to lower drug prices
Trump announces new drug pricing deals with 9 drugmakers
Trump reportedly plans to announce new drug pricing deals with nearly a dozen drugmakers
